CAS: 882257-11-6; 1-(5-((2,3-Dichlorophenyl)Thio)-4-Nitrothiophen-2-yl)Ethan-1-One

该化合物是一种合成化合物,主要针对其在药用化学中的潜在应用进行了研究,特别是在药物开发方面,尽管分子重量,结构和溶解性等具体特征可能各不相同,但P005091等化合物通常具有适合生物活动的特点,包括与特定生物目标的相互作用;这些物质经常在临床前研究中因其功效,安全性和药用基因特征而得到评估;此外,它们可能拥有独特的功能组,有助于其再活性和稳定性;与许多合成化合物一样,了解其特性对于确定其潜在的治疗用途和行动机制至关重要;建议提供关于其具体特性的详细信息,包括光谱数据或生物活动,咨询专门研究化学物质的科学文献或数据库.

结构式图片

欧盟法规

C&L通报

上下游产品

5-acetyl-2-chloro-3-nitrothiophene 2,3-dichlorobenzenethiol 2-acetyl-5-chlorothiophene1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanol

合成工艺路线路线简述

  • 17231-95-7 + 42456-75-7 = 882257-11-6
    反应条件:1.1 Reagents: Sodium Methoxide Solvents: Methanol; 15 Min,Rt1.2 1 H,Rt
    标题:Selective Dual Inhibitors Of The Cancer-Related Deubiquitylating Proteases Usp7 And Usp47
    作者:Weinstock,Joseph; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2012 卷标:3(10) 页码:789-792]

    6310-09-4 = 882257-11-6
    反应条件:1.1 Reagents: Fuming Nitric Acid; Cooled; 30 Min,Rt2.1 Reagents: Sodium Methoxide Solvents: Methanol; 15 Min,Rt2.2 1 H,Rt
    标题:Selective Dual Inhibitors Of The Cancer-Related Deubiquitylating Proteases Usp7 And Usp47
    作者:Weinstock,Joseph; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2012 卷标:3(10) 页码:789-792
📜2-乙酰基-5-氯噻酚置于硝酸,Sodium Methylate体系中,用 甲醇 作为反应溶剂,化学反应 1.75H,反应生成 1-[5-[(2,3-二氯苯基)硫基]-4-硝基-2-噻吩基]-乙酮
参考文献:Selective Dual Inhibitors Of The Cancer-Related Deubiquitylating Proteases Usp7 And Usp47
标题:Selective Dual Inhibitors Of The Cancer-Related Deubiquitylating Proteases Usp7 And Usp47
摘要:Inhibitors Of The Cancer-Related Cysteine Isopeptidase Human Ubiquitin-Specific Proteases 7 (Usp7) And 47 (Usp47) Are Considered To Have Potential As Cancer Therapeutics,Owing To Their Ability To Stabilize The Tumor Suppressor P53 And To Decrease Dna Polymerase Beta (Pol Beta),Both Of Which Are Potential Anticancer Effects. A New Class Of Dual Small Molecule Inhibitors Of These Enzymes Has Been Discovered. Compound 1,A Selective Inhibitor Of Usp7 And Usp47 With Moderate Potency,Demonstrates Inhibition Of Usp7 In Cells And Induces Elevated P53 And Apoptosis In Cancer Cell Lines. Compound 1 Has Been Shown To Demonstrate Modest Activity In Human Xenograft Multiple Myeloma And B-Cell Leukemia In Vivo Models. This Activity May Be The Result Of Dual Inhibition Of Usp7 And Usp47. To Address Issues Regarding Potency And Developability,Analogues Of Compound 1 Have Been Synthesized And Tested,Leading To Improvements In Potency,Solubility,And Metabolic Reactivity Profile. Further Optimization Is Expected To Yield Preclinical Candidates And,Ultimately,Clinical Candidates For The Treatment Of Multiple Myeloma,Prostate Cancer,And Other Cancers.
DOI:10.1021/ml200276J

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011 Jun;60(1-2):61-8. doi: 10.1007/s12013-011-9185-5. Xia, J., He, Y., Meng, B., Chen, S., Zhang, J., Wu, X., ... & Zhou, W. (2020). NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma. Molecular oncology, 14(4), 763-778.

合成参考文献


参考文献:10.1021/ml200276j
摘要:Weinstock J, Wu J, Cao P, Kingsbury WD, McDermott JL, Kodrasov MP, McKelvey DM, Suresh Kumar KG, Goldenberg SJ, Mattern MR, Nicholson B. Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med Chem Lett. 2012 Oct 11;3(10):789–92.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知